Nonalcoholic Steatohepatitis: Epidemiology, Screening, Risk Assessment, Diagnosis, and Management

  • Author: Philip N. Newsome, PhD, FRCPE (More Info)
  • Editor In Chief: Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
  • Last Reviewed: 8/23/19 (What's New)

Summary

  • There are currently no FDA-approved agents indicated for treatment of NAFLD or NASH
  • Patients with NAFLD are managed using several modalities, with most efforts directed toward lifestyle modifications promoting sustained weight loss and management of metabolic syndrome components such as dyslipidemia, hypertension, and T2DM
  • Lifestyle Interventions
    • The management of patients with NAFLD principally involves lifestyle interventions aimed at sustained weight loss
      Medical Interventions
        Management of Common Comorbidities
          Bariatric Surgery
            Pharmacologic Management of NASH
              Investigational Agents

            Action required